Moreover, anti-CTLA-4 monoclonal antibody (mAb) therapy in preclinical cancer models produced antitumor activity, both as monotherapy and in combination with other therapeutic modalities [3, 18–21], providing the rationale for clinical development of human monoclonal antibodies that target CTLA-4. Here, CTLA4 is linked to cancer.